Abstract: Objective: To evaluate the response of escalated CTOP consisting of increased dose THP (60mg/m²) in NHL and clarify how the side-effect occur (especially for the occurrence of cardiotoxicity ) when the total dose of THP (pirarubicin) is increased. To study the safty of increasing the dose of THP. Methods: From August 2001 to May 2003, 39 patients with chemonaive NHL(non Hodgkin's lymphoma) received either escalated CTOP (n=19) or conventional CTOP(n=20). All these patients received 2 cycles chemotherapy at least. The response and side effect were observed after receiving chemotherapy. Results: Escalated CTOP achieved better complete remission rate than conventional CTOP (47.4%vs21.1%). Time to achieved complete remission was shortened, too (P<0.01). As to the side effect the escalated CTOP is similar to conventional CTOP. There was no significant difference between the two protocols. Conclusion: Increment of the THP dose consisted in CTOP regimen can improve efficacy. On the other hand, chemotherapy-induced toxicity was not significant intensified when dose of THP increased. The escalated THP can be used safely.